MYD88 and diffuse large B-cell lymphoma: Several tumors with the MYD88 L265P mutation did not respond to ibrutinib, lenalidomide, and DA-EPOCH-R, suggesting that additional genetic and/or epigenetic attributes of DLBCL tumors may influence response to this regimen.